Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$43.53-1.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · SUPN
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(25.0) + peer(0.2*10.6) + term(0.0) → 10.88% (capped ±15.0)
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition On August 3, 2026, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus and Invidior Pharmaceuticals, Inc. ("Invidior") have entered into a definitive agreement to combine in an all-stock merger of equals…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On July 22, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it will report its business results for the second quarter of 2026 after the market closes on Tuesday, August 4, 2026. The Company will host a conference call and webcast on Tuesday, August 4, 2026 at 4:30 p.m. E.T. to discuss its second quarter 2026 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorpo…
Results of Operations and Financial Condition. On May 5, 2026, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the first quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Tuesday, May 5, 2026, to present the business and financial results. A live…
Results of Operations and Financial Condition. On April 22, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it will report its business results for the first quarter of 2026 after the market closes on Tuesday, May 5, 2026. The Company will host a conference call and webcast on Tuesday, May 5, 2026 at 4:30 p.m. E.T. to discuss its first quarter 2026 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated h…
Results of Operations and Financial Condition. On February 24, 2026, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the fourth quarter ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Tuesday, February 24, 2026, to present the business and financial…
Results of Operations and Financial Condition. On February 12, 2026, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the fourth quarter of 2025 after the market closes on Tuesday, February 24, 2026. The Company will host a conference call and webcast on Tuesday, February 24, 2026 at 4:30 p.m. E.T. to discuss its fourth quarter 2025 financial and business results. A copy of this press release is furnished as Exhibit 99.1 heret…
Results of Operations and Financial Condition. On November 4, 2025, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the third quarter September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Tuesday, November 4, 2025, to present the business and financial results.…
Results of Operations and Financial Condition. On October 21, 2025, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the third quarter of 2025 after the market closes on Tuesday, November 4, 2025. The Company will host a conference call and webcast on Tuesday, November 4, 2025 at 4:30 p.m. E.T. to discuss its third quarter 2025 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and…
Results of Operations and Financial Condition. On August 5, 2025, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the second quarter June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Tuesday, August 5, 2025, to present the business and financial results. A live…
Results of Operations and Financial Condition. On July 22, 2025, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the second quarter of 2025 after the market closes on Tuesday, August 5, 2025. The Company will host a conference call and webcast on Tuesday, August 5, 2025 at 4:30 p.m. E.T. to discuss its second quarter 2025 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is i…
Results of Operations and Financial Condition. On May 6, 2025, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the first quarter March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Tuesday, May 6, 2025, to present the business and financial results. A live webcas…
Results of Operations and Financial Condition. On April 23, 2025, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025. The Company will host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. E.T. to discuss its first quarter 2025 financial and business results. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorpor…
Results of Operations and Financial Condition. On February 25, 2025, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the fourth quarter and full year ended December 31, 2024. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Tuesday, February 25, 2025, to present the business…
Results of Operations and Financial Condition. On February 11, 2025, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the fourth quarter and full year of 2024 after the market closes on Tuesday, February 25, 2025. The Company will host a conference call and webcast on Tuesday, February 25, 2025 at 4:30 p.m. E.T. to discuss its fourth quarter and full year 2024 financial and business results. A copy of this press release is fur…
Results of Operations and Financial Condition. On November 4, 2024, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2024 and announcing topline data from the open-label Phase 2a study of SPN-817 for treatment-resistant seizures. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. As previously announced, Supernus is hosting a confe…
Results of Operations and Financial Condition. On October 21, 2024, Supernus Pharmaceuticals, Inc. issued a press release announcing that it expects to report its business results for the third quarter 2024 after the market closes on Monday, November 4, 2024. The Company will host a conference call and webcast on Monday, November 4, 2024 at 4:30 p.m. E.T. to discuss its third quarter 2024 business and financial results. A copy of this press release is furnished as Exhibit 99.1 hereto and is i…